Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Total Current Liabilities
All obligations due within one year.
Entera Bio Ltd.NASDAQ: ENTX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 2.9% from a year ago
Total current liabilities stood at $1.58M at the end of Q1 FY2026, down 2.9% from a year earlier and down 28.5% from the prior quarter. Over 3 fiscal years it compounded at +18.0% a year.
Context
- Total current liabilities amounted to 12.0% of total assets at the end of Q1 FY2026, up 4.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -2.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.2M USD
- Year-over-year change
- +87.3%
- 4-year CAGR
- -8.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.2M | +87.3% |
| FY2024 | 2024-12-31 | 1.18M | +7.8% |
| FY2023 | 2023-12-31 | 1.09M | -18.6% |
| FY2022 | 2022-12-31 | 1.34M | -57.6% |
| FY2021 | 2021-12-31 | 3.16M | — |
Total Current Liabilities vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 total current liabilities of $1.58M is the 9th highest of the 10 companies compared; the peer median is $10.24M.
- Its year-over-year change of -2.9% is the 5th highest of 10, against a peer median of -20.5%.
- Total current liabilities amounts to 12.0% of total assets for ENTX, versus a peer median of 16.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $249.24M | +19.7% | +19.6% | 133.7% | |
| Mar 2026 | $37.92M | +38.8% | -23.3% | 76.2% | |
| Mar 2026 | $29.23M | +51.3% | +56.6% | 21.9% | |
| Mar 2026 | $19.34M | -38.2% | -39.1% | 16.4% | |
| Mar 2026 | $10.24M | -22.4% | +7.6% | 3.8% | |
IRDOpus Genetics, Inc. | Mar 2026 | $9.34M | -61.5% | +41.4% | 14.0% |
| Mar 2026 | $6.07M | +26.9% | +27.3% | 20.4% | |
| Mar 2026 | $5.49M | -81.2% | -25.7% | 9.3% | |
| Mar 2026 | $1.58M | -2.9% | +18.0% | 12.0% | |
| Apr 2026 | $1.5M | -20.5% | -1.2% | 10.1% | |
| Peer median (excluding ENTX) | $10.24M | -20.5% | +7.6% | 16.4% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.